Genetic testing for cancer predisposition

Annual Review of Medicine

Volumn 52, Issue , 2001, Pages 371-400

  Eng, C ^a   Hampel, H ^a   De la Chapelle, A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Inherited neoplasia syndrome; Mutation; Predictive testing

Indexed keywords

ADENOMATOUS POLYP; BREAST CANCER; CANCER GENETICS; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; FAMILIAL CANCER; GENETIC ANALYSIS; GENETIC COUNSELING; HUMAN; JUVENILE POLYP; MUTATION; PATIENT CARE; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; REVIEW; SIPPLE SYNDROME; VON HIPPEL LINDAU DISEASE;

BREAST NEOPLASMS; CAUSALITY; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HAMARTOMA SYNDROME, MULTIPLE; HIPPEL-LINDAU DISEASE; HUMANS; INCIDENCE; LI-FRAUMENI SYNDROME; MELANOMA; MULTIPLE ENDOCRINE NEOPLASIA; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; OVARIAN NEOPLASMS; PEDIGREE; PEUTZ-JEGHERS SYNDROME; SENSITIVITY AND SPECIFICITY;

EID: 0035126870     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.52.1.371     Document Type: Review

References (75)

1. Molecular genetic testing in hereditary cancer
2. RET proto-oncogene in the development of human cancer
3. The clinical and age-at-onset distribution for the MEN-2 syndrome
4. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10
5. Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2
6. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis
7. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation
8. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A
9. Multiple endocrine neoplasia type 2 and medullary thyroid carcinoma
10. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma
11. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma
12. Statement of the American Society of Clinical Oncology - Genetic testing for cancer susceptibility
13. Familial multiple endocrine neoplasia type 1. A new look at pathophysiology
14. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma
15. Positional cloning of the gene for multiple endocrine neoplasia type 1 (MEN 1) gene
16. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish kindred
17. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in a subset of families
18. Von Hippel-Lindau disease: A genetic study
19. Identification of the von Hippel-Lindau disease tumor suppressor gene
20. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene
21. Germline mutation profile of the VHL gene in von Hippel-Lindau disease in sporadic hemangioblastoma
22. Germline mutations in the Von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype
23. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype
24. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma
25. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma
26. Genetic predisposition to phaeochromocytoma: Analysis of candidate genes GDNF, RET and VHL
27. Consequences of direct genetic testing for germ-line mutations in the clinical management of families with multiple endocrine neoplasia type 2
28. NCCN practice guidelines: Genetics/familial high risk cancer
29. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
30. Identification of the breast cancer susceptibility gene BRCA2
31. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
32. Population genetics of BRCA1 and BRCA2
33. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genesin breast cancer families
34. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer
35. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families
36. Genetics of Cowden syndrome - Through the looking glass of oncology
37. Will the real Cowden syndrome please stand up: Revised diagnostic criteria
38. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
39. Mutation spectrum and genotypephenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation
40. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome
41. Molecular classification of the inherited hamartoma polyposis syndromes: Clearing the muddied waters
42. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer
43. Germline PTEN mutations in Cowden syndrome-like families
44. Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers
45. Cowden's disease
46. Third International Workshop on collaborative interdisciplinary studies of p53 and other predisposing genes in Li-Fraumeni syndrome
47. Germ-line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
48. Germ-line mutations of TP53 in Li-Fraumeni families: An extended study of 39 families
49. Genetic susceptibility to non-polyposis colorectal cancer
50. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC)
51. Cancer risk in mutation carriers of DNA-mismatch repair genes
52. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer
53. Sensitivity and specificity of clinical criteria for hereditary nonpolyposis colorectal cancer-associated mutations in MSH2 and MLH1
54. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease
55. Population-based molecular detection of hereditary nonpolyposis colorectal cancer
56. Recommendations for the follow-up care of individuals with cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Study Consortium
57. Clinical surveillance recommendations adopted for HNPCC
58. Increased risk of cancer in Peutz-Jeghers syndrome
59. Lessons from hereditary colorectal cancer
60. Care of patients and their families with familial adenomatous polyposis
61. Peutz-Jeghers syndrome
62. Increased risk for cancer in patients with the Peutz-Jeghers syndrome
63. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome
64. Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer
65. Mutations in the SMAD4/DPC4 gene in juvenile polyposis
66. The hereditary variant of malignant melanoma
67. Molecular genetics of familial cutaneous melanoma
68. Melanoma genetics: An update with focus on the CDKN2A-(p16)/ARF tumor supressors
69. CDKN2A (P16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas
70. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM)
71. Mutations of the CDKN2/p16Ink4A gene in Australian melanoma kindreds
72. The genetics of hereditary melanoma and nevi: 1998 update
73. Mortality from second tumors among longterm survivors of retinoblastoma
74. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC
75. Over-representation of PPARy sequence variants in sporadic cases of glioblastoma multiforme: Preliminary evidence for common low penetrance modifiers for brain tumour riskin the general population